Search results
Results from the WOW.Com Content Network
In September 2020, Sinovac began Phase I–II trials in China on children and adolescents ages 3–17. [92] In May 2021, Sinovac began Phase IIb trials in China with 500 participants for children and adolescents 3–17 years old. [93] In June 2021, it was announced that the vaccine was safe and immunogenic in this age group. [94]
The World Health Organization (WHO) said on Tuesday it has approved a COVID-19 vaccine made by Sinovac Biotech for emergency use listing, paving the way for a second Chinese shot to be used in ...
Offering Sinovac Biotech COVID-19 vaccines to the public in Singapore for the first time since Friday, several private clinics reported overwhelming demand for the Chinese-made shot, despite ...
A spokesperson for the UN agency told Reuters that the ministry will continue to communicate with COVAX facility to receive vaccines in the coming months. North Korea rejects offer of nearly 3 ...
CoronaVac is an inactivated virus COVID-19 vaccine developed by Sinovac. [7] It has been in Phase III clinical trials in Brazil, [8] Chile, [9] Indonesia, [10] Philippines, [11] and Turkey. [12] It relies on traditional technology similar to the Sinopharm BIBP vaccine and Covaxin, otherwise known as inactivated-virus COVID-19 vaccines in Phase ...
Thailand Food and DrugAdministration (FDA) on Monday gave emergency use authorisationfor the COVID-19 vaccine of Sinovac Biotech, paving theway for the country's first coronavirus inoculations.
National regulatory authorities have granted full or emergency use authorizations for 40 COVID-19 vaccines.. Ten vaccines have been approved for emergency or full use by at least one stringent regulatory authority recognized by the World Health Organization (WHO): Pfizer–BioNTech, Oxford–AstraZeneca, Sinopharm BIBP, Moderna, Janssen, CoronaVac, Covaxin, Novavax, Convidecia, and Sanofi ...
Indonesia’s Food and Drug Authority on Monday green-lighted emergency use of the COVID-19 vaccine produced by China-based Sinovac Biotech Ltd., with vaccinations of high-risk groups expected to ...